Replimune Melanoma Drug Snags Coveted FDA Approval After Yearlong Clash, Two Rejections on August 07, 2026 Accelerated Advanced Melanoma Approved Complete Response Letter IGNYTE trial melanoma drug Opdivo Phase 3 confirmatory trial Replimune RETINITIS PIGMENTOSA 1 Tudriqev United States Food and Drug Administration +
Replimune’s Twice‑Rejected Melanoma Drug Prevails in FDA Adcomm Vote on July 31, 2026 Advanced Melanoma Advisory Committees Cellular Tissue gene therapy melanoma drug nivolumab Opdivo Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +
Replimune to ask FDA for re‑review of melanoma drug, as agency stands by past rejections on May 29, 2026 Accelerated Advanced Melanoma Approved Complete Response Letter IGNYTE melanoma drug nivolumab Opdivo Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +